MAPT and Alzheimer disease: SCN10A (Sodium channel protein type 10 subunit alpha), a target of bupivacaine, was linked with MAPT (tau) and PSEN1 (presenilin1), which were associated with the pathological hallmarks of AD, via SCN1A (sodium channel protein type 1 subunit alpha), a target of topiramate (Figure 4C).